Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1

Conditions

Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Gemcitabine 87Cisplatin 66Cystectomy 38pembrolizumab 35Docetaxel 25Nivolumab 24durvalumab 21Paclitaxel 19Magnetic Resonance Spectroscopy 18Radiotherapy 17Mitomycin 17Carboplatin 16atezolizumab 15Doxorubicin 14Cystoscopy 14BCG Vaccine 13Surveys and Questionnaires 12Standard of Care 12avelumab 11Sunitinib 10tremelimumab 9Transurethral Resection of Bladder 9Ipilimumab 9Filgrastim 9Blood Specimen Collection 9enfortumab vedotin 8Specimen Handling 8Neoadjuvant Therapy 8Methotrexate 8Methods 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Urinary Bladder Neoplasms × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

NCT00622973 2011-10-12

USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases

Insel Gruppe AG, University Hospital Bern

Phase 3 Completed
130 enrolled
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡